Japan's Meiji Seika Kaisha is to launch two new products in the second half of this fiscal year and increase its sales team by 20%, according to the Nikkei Weekly. The Japanese financial newspaper claims Meiji will double sales-force hiring from the previous fiscal year, which ended in March, to a total of 800. During the period, the firm will release one antidepressant, whilst granting sales rights to its mainstay antibiotics to a Russian firm. Lastly, the Nikkei says Meiji will divert its focus from Asia to emerging markets such as eastern Europe and the Middle East.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze